Editorial: Current insights in melanoma immunology, immune escape and immunotherapy advances
Front Immunol. 2026 May 18;17:1868805. doi: 10.3389/fimmu.2026.1868805.…
Phase I trial of intravenous VCN-01 oncolytic adenovirus and durvalumab in patients with head and neck metastatic squamous cell carcinoma refractory to immunotherapy
Clin Cancer Res. 2026 Jun 8. doi: 10.1158/1078-0432.CCR-26-0601.…
Five-Year Survival with Tebentafusp in Metastatic Uveal Melanoma
Ann Oncol. 2026 May 19:S0923-7534(26)00879-3. doi: 10.1016/j.annonc.2026.05.695.…
Uveal melanoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up
ESMO Open. 2026 Apr;11(4):106888. doi: 10.1016/j.esmoop.2026.106888.…
Recent Advances in Understanding the Biology of Castration-Resistant Prostate Cancer
Urol Clin North Am. 2026 May;53(2):303-315. doi: 10.1016/j.ucl.2026.02.012.…
A rise in double-strand breaks sensitizes tumors to oxidative metabolism inhibitors
Biomed Pharmacother. 2026 Mar 10;197:119184. doi: 10.1016/j.biopha.2026.119184.…
Efficacy and safety of atezolizumab plus bevacizumab in MSI-like metastatic colorectal cancer: a multicenter, single-arm, phase II, open-label clinical trial
ESMO Open. 2025 Dec 2;10(12):105892. doi: 10.1016/j.esmoop.2025.105892.…
Comment on: “Tebentafusp Versus Nivolumab Plus Ipilimumab for Metastatic Uveal Melanoma: An E‑Value Sensitivity Analysis Assessing Effect of Unmeasured Confounders on Observational Associations”
Clin Drug Investig. 2025 Oct 28. doi: 10.1007/s40261-025-01468-1.…
Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 patients
Clin Cancer Res. 2025 Sep 12. doi: 10.1158/1078-0432.CCR-25-1513.…
Toxicity and Biodistribution of the Oncolytic Virus VCN-01 Following Intracranial Injection in Syrian Hamsters
Hum Gene Ther. 2025 Aug 29. doi: 10.1177/10430342251372091. Online…
Final overall survival and safety analyses of the phase 3 PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer
Ann Oncol. 2025 Jul 16:S0923-7534(25)00852-X. doi: 10.1016/j.annonc.2025.07.003.…
Molecular determinants of survival in metastatic uveal melanoma: The impact of SF3B1 mutations
Eur J Cancer. 2025 Jun 24;226:115591. doi: 10.1016/j.ejca.2025.115591.…
